NECLIFENSENectar Lifesciences Limited· PharmaceuticalsMediumNeutral
Announced Fri, 13 Mar · 11:20 IST

Nectar Lifesciences Limited has informed the Exchange with copy of minutes of Postal Ballot

Board & Shareholder Meetings View source PDF

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.6%1-day move
₹11.35
prior close
₹11.35
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.9+0.9+0.3-2.6-4.3-0.3-0.7-3.5-7.1-4.8+5.3+13.6+4.7
Up moveDown movePending
AI summary

Nectar Lifesciences Limited has filed the minutes of its postal ballot conducted through electronic voting from January 30, 2026 to February 28, 2026, with results declared on March 1, 2026. All three resolutions were approved with overwhelming majority: (1) appointment of Mr. Sushil Kapoor as a Director liable to retire by rotation (99.99% in favor), (2) his appointment as Wholetime Director designated as Director (Finance) for three years effective December 4, 2025 (99.99% in favor), and (3) adoption of a new Memorandum of Association with amended object clause (99.08% in favor). Mr. Kapoor's remuneration was fixed at ₹3 lakh per month plus a one-month salary bonus annually and standard benefits. The promoter group holding ~10.07 crore shares (about 52% of the company) voted 100% in favor of all resolutions, while public institutional investors unanimously opposed the MOA amendment (100% against).

Likely market impact

The company has formally locked in a three-year finance director appointment and widened its permitted business activities via the MOA amendment, giving it room to diversify. The unanimous promoter backing signals management stability, but the unusual 100% opposition from public institutional holders on the MOA change may raise governance questions among minority investors.